Figure 1.

Study design and disposition of patients. ^aStandard antidepressant treatment was initiated or optimized on day 1.  ^bPatients who completed the double-blind phase and either entered the follow-up phase or had adverse events evaluated after the double-blind treatment phase. Note: Three patients were not included in the efficacy analysis dataset due to discontinuing prior to receiving study drug or not providing postbaseline efficacy data.